Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom

Fig. 3

Cost-effectiveness acceptability curves (a) Canada (b) UK‡. Note: QALY, quality-adjusted life-year; Cost-effectiveness threshold for Canada and UK are $40,000–50,000 and £20,000 per QALY gained, respectively; ‡Figure presented for the UK is based on Scenario UK1, UK2 is very similar (data not shown)

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us